Department of Interventional Medicine, Binzhou People's Hospital, affiliated to Shandong First Medical University, Binzhou, China.
Department of Oncology, Binzhou People's Hospital, affiliated to Shandong First Medical University, Binzhou, China.
Minim Invasive Ther Allied Technol. 2024 Oct;33(5):278-286. doi: 10.1080/13645706.2024.2372308. Epub 2024 Jun 26.
This study aims to assess the safety and clinical efficacy of percutaneous splenic embolization (PSE) and splenectomy as approaches to treating cases of traumatic splenic rupture (TSR).
Eligible articles published throughout August 2023 were identified. Endpoints compared between PSE and splenectomy patient groups included operative time, intraoperative hemorrhage, duration of hospitalization, postoperative complication rates, and measures of immune function.
Thirteen studies, involving 474 and 520 patients in the PSE and splenectomy groups respectively, were incorporated into this meta-analysis. As compared to the splenectomy group, individuals treated PSE exhibited a significant reduction in pooled operative time ( < 0.00001) and hospitalization duration ( < 0.00001), with corresponding reductions in rates of intraoperative hemorrhage ( < 0.00001), total complications ( < 0.0001), incisional infection ( < 0.0001), ileus ( = 0.0004), and abdominal infection ( = 0.02). The immune status of these PSE group patients was also improved, as evidenced by significantly higher pooled CD4 (30 days), CD4/CD8 (30 days), and CD3 (30 days) values ( < 0.0001, 0.0001, and 0.0001, respectively).
Compared to splenectomy, PSE-based TSR treatment can significantly reduce operative time, rate of postoperative complications, and incidence of intraoperative hemorrhage, while improving post-procedural immune functionality.
本研究旨在评估经皮脾脏栓塞术(PSE)和脾脏切除术治疗创伤性脾破裂(TSR)的安全性和临床疗效。
纳入截至 2023 年 8 月发表的合格文章。比较 PSE 和脾切除术患者组的终点包括手术时间、术中出血量、住院时间、术后并发症发生率和免疫功能指标。
共纳入 13 项研究,PSE 组和脾切除术组分别纳入 474 例和 520 例患者。与脾切除术组相比,PSE 组的汇总手术时间( < 0.00001)和住院时间( < 0.00001)显著缩短,术中出血量( < 0.00001)、总并发症发生率( < 0.0001)、切口感染发生率( < 0.0001)、肠梗阻发生率( = 0.0004)和腹腔感染发生率( = 0.02)降低。这些 PSE 组患者的免疫状态也得到改善,表现为汇总的 CD4(30 天)、CD4/CD8(30 天)和 CD3(30 天)值明显更高( < 0.0001、0.0001 和 0.0001)。
与脾切除术相比,基于 PSE 的 TSR 治疗可显著缩短手术时间、术后并发症发生率和术中出血量,同时改善术后免疫功能。